secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2022-09-13T23:59:59+00:00
Accession:  0001193125-22-243702
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam prices $900M convertible senior notes at 1.00% due 2027; conversion premium 35%
--------------------------------------------------------------------------------

- Principal $900M (greenshoe up to $135M); interest 1.00% semi-annual; maturity Sept 15, 2027.
- Initial conversion price ~$286.20/share, 35% premium over $212.00 close on Sept 12, 2022.
- Net proceeds est. $883.2M (or $1,015.8M with greenshoe); $762M to repay credit facility, $103.1M for capped call.
- Capped call cap price $424.00/share, reducing dilution upon conversion; counterparties may hedge in open market.
- Offering expected to close Sept 15, 2022, subject to customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000119312522243702/0001193125-22-243702-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000119312522243702/d397120d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-243702

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer